What is the current valuation of the irritable bowel-syndrome-treatment market in Italy?

The market valuation was $68.17 Million in 2024. Read More

What is the projected market size for the irritable bowel-syndrome-treatment market in Italy by 2035?

The market is projected to reach $157.21 Million by 2035. Read More

What is the expected CAGR for the irritable bowel-syndrome-treatment market in Italy during the forecast period 2025 - 2035?

The expected CAGR is 7.89% during the forecast period. Read More

Which companies are the key players in the irritable bowel-syndrome-treatment market in Italy?

Key players include AbbVie Inc, Boehringer Ingelheim GmbH, Takeda Pharmaceutical Company Limited, and others. Read More

What are the main segments of the irritable bowel-syndrome-treatment market in Italy?

The main segments include IBS-D, IBS-C, and IBS-M. Read More

How did the IBS-D segment perform in terms of valuation in 2024?

The IBS-D segment had a valuation of $25.0 Million in 2024. Read More

What is the valuation range for the drug type Linaclotide in the irritable bowel-syndrome-treatment market?

The valuation range for Linaclotide is $15.0 Million to $35.0 Million. Read More

Which end-user segment had the highest valuation in 2024?

The Hospitals segment had the highest valuation at $27.27 Million in 2024. Read More

What is the projected growth for the IBS-C segment by 2035?

The IBS-C segment is expected to grow from $30.0 Million to $70.0 Million by 2035. Read More

How does the performance of the Rifaximin drug type compare to others in the market?

Rifaximin had a valuation range of $20.0 Million to $40.0 Million, indicating strong market performance. Read More

Italy Irritable Bowel Syndrome Treatment Market

Italy Irritable Bowel Syndrome Treatment Market Research Report: Size, Share, Trend Analysis By Types (IBS-D, IBS-C, IBS-M), By Drug Type (Lubiprostone, Linaclotide, Rifaximin, Eluxadoline, Alosetron), and By End-user (Hospitals, Clinics, Research Laboratories, Others) - Growth Outlook & Industry Forecast 2025 To 2035

Forecast Period

2025 - 2035

CAGR

7.89%

2024 Market Size

$ 68.17 Million

2035 Market Size

$ 157.21 Million

Healthcare ● Updated August 2026 Report ID: MRFR/HC/47598-HCR | Pages: 200 | Author: Satyendra Maurya, Garvit Vyas

Summary Table of Contents Segmentation Download PDF

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Food, Beverages & Nutrition, BY Type (USD Million)
  1. 4.1.1 IBS-D
  2. 4.1.2 IBS-C
  3. 4.1.3 IBS-M
2. 4.2 Food, Beverages & Nutrition, BY Drug Type (USD Million)
  1. 4.2.1 Lubiprostone
  2. 4.2.2 Linaclotide
  3. 4.2.3 Rifaximin
  4. 4.2.4 Eluxadoline
  5. 4.2.5 Alosetron
3. 4.3 Food, Beverages & Nutrition, BY End-User (USD Million)
  1. 4.3.1 Hospitals
  2. 4.3.2 Clinics
  3. 4.3.3 Research Laboratories
  4. 4.3.4 Others
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Food, Beverages & Nutrition
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Food, Beverages & Nutrition
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 AbbVie Inc (US)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Boehringer Ingelheim GmbH (DE)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Takeda Pharmaceutical Company Limited (JP)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 GlaxoSmithKline plc (GB)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 AstraZeneca PLC (GB)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 Johnson & Johnson (US)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 Pfizer Inc (US)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 Merck & Co., Inc. (US)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 ITALY MARKET ANALYSIS BY TYPE
3. 6.3 ITALY MARKET ANALYSIS BY DRUG TYPE
4. 6.4 ITALY MARKET ANALYSIS BY END-USER
5. 6.5 KEY BUYING CRITERIA OF FOOD, BEVERAGES & NUTRITION
6. 6.6 RESEARCH PROCESS OF MRFR
7. 6.7 DRO ANALYSIS OF FOOD, BEVERAGES & NUTRITION
8. 6.8 DRIVERS IMPACT ANALYSIS: FOOD, BEVERAGES & NUTRITION
9. 6.9 RESTRAINTS IMPACT ANALYSIS: FOOD, BEVERAGES & NUTRITION
10. 6.10 SUPPLY / VALUE CHAIN: FOOD, BEVERAGES & NUTRITION
11. 6.11 FOOD, BEVERAGES & NUTRITION, BY TYPE, 2024 (% SHARE)
12. 6.12 FOOD, BEVERAGES & NUTRITION, BY TYPE, 2024 TO 2035 (USD Million)
13. 6.13 FOOD, BEVERAGES & NUTRITION, BY DRUG TYPE, 2024 (% SHARE)
14. 6.14 FOOD, BEVERAGES & NUTRITION, BY DRUG TYPE, 2024 TO 2035 (USD Million)
15. 6.15 FOOD, BEVERAGES & NUTRITION, BY END-USER, 2024 (% SHARE)
16. 6.16 FOOD, BEVERAGES & NUTRITION, BY END-USER, 2024 TO 2035 (USD Million)
17. 6.17 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 Italy MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY TYPE, 2025-2035 (USD Million)
  2. 7.2.2 BY DRUG TYPE, 2025-2035 (USD Million)
  3. 7.2.3 BY END-USER, 2025-2035 (USD Million)
2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.3.1
1. 7.4 ACQUISITION/PARTNERSHIP
7.4.1

Certified Researchers

Customize Report

Italy Irritable Bowel Syndrome Treatment Market Segmentation

Italy Irritable Bowel Syndrome Treatment Market By Type (USD Million, 2025-2035)

IBS-D
IBS-C
IBS-M

Italy Irritable Bowel Syndrome Treatment Market By Drug Type (USD Million, 2025-2035)

Lubiprostone
Linaclotide
Rifaximin
Eluxadoline
Alosetron

Italy Irritable Bowel Syndrome Treatment Market By End-User (USD Million, 2025-2035)

Hospitals
Clinics
Research Laboratories
Others

Certified Researchers

Customize Report

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”

Rob Kooiker Group Product Manager HVAC & Fire Protection GMA

“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”

Akif Moroglu Strategy & Business Development Director

“The Automotive 48V ECU Components Procurement Intelligence Study” was a complex project, but the Market Research Future (MRFR) team handled it with quality, agility, and customer-centricity. They delivered all requested data on time and within the agreed scope. The team, including Shubhendra Anand and Rahul Gotadki, was always readily available to clarify questions and swiftly implement necessary adjustments, driving the project to a successful conclusion within a very demanding timeframe.
I would also like to specifically commend Akshay Agarwal for his responsiveness and support at every stage—from our initial inquiry on May 6th through to final delivery on June 18th. His dedication made the entire process seamless.”